Results 181 to 190 of about 1,660,326 (362)
This study demonstrates that KRAS and GNAS mutations are more prevalent in patients with resected intraductal papillary mucinous neoplasms (IPMN) compared to those under clinical surveillance. GNAS mutations significantly differ between the two patient cohorts, indicating that their absence may serve as a potential biomarker to support conservative ...
Christine Nitschke+12 more
wiley +1 more source
The Patent Office as Guardian of the Public Interest in Trade-Mark Registration Proceedings
Walter J. Derenberg
openalex +2 more sources
PATENT DUCTUS ARTERIOSUS SOME NOTES ON PROGNOSIS AND ON PULMONARY HYPERTENSION [PDF]
Mark Campbell
openalex +1 more source
Rethinking Novelty in Patent Law [PDF]
The novelty requirement seeks to ensure that a patent will not issue if the public already possesses the invention. Although gauging possession is usually straightforward for simple inventions, it can be difficult for those in complex fields like ...
Seymore, Sean B.
core +3 more sources
We quantified and cultured circulating tumor cells (CTCs) of 62 patients with various cancer types and generated CTC‐derived tumoroid models from two salivary gland cancer patients. Cellular liquid biopsy‐derived information enabled molecular genetic assessment of systemic disease heterogeneity and functional testing for therapy selection in both ...
Nataša Stojanović Gužvić+31 more
wiley +1 more source
Coarctation of the Aorta Complicated by Patency of the Ductus Arteriosus [PDF]
Arnold L. Johnson+3 more
openalex +1 more source
The authors applied joint/mixed models that predict mortality of trifluridine/tipiracil‐treated metastatic colorectal cancer patients based on circulating tumor DNA (ctDNA) trajectories. Patients at high risk of death could be spared aggressive therapy with the prospect of a higher quality of life in their remaining lifetime, whereas patients with a ...
Matthias Unseld+7 more
wiley +1 more source